Surv.AI Says

Surv.AI Says! Compete to identify patients’ perspectives on the new nAMD & DME treatments. Then, a panel of experts will break down what these mean for your practice.

Click here to register


  • Raman Bhakhri, OD
  • Shaun Ittiara, MD, FACS, FASRS
  • Dimitra Skondra, MD, PhD


For patients with nAMD or DME, intravitreal anti-VEGF injections are the standard of care – but poor adherence and high treatment burden have led to suboptimal visual outcomes in the real world compared with clinical trial results. New anti-VEGF therapies are now available, and so are new technologies that can give eye care providers insights into how patients feel about these diseases and treatments.

In this engaging, interactive, and innovative session, the audience will vote on the issues they think patients and eye care providers are facing in regard to nAMD, DME, and its treatments – and then see the insights that AI has collected online about these questions. A panel of expert faculty will show what these insights mean for your practice!

Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Outline disease and treatment-specific concerns among patients with nAMD that impact quality of life
  • Summarize disease and treatment-specific concerns among patients with DME that impact quality of life
  • Apply real-world evidence and best practices toward the development of treatment plans for the management of nAMD
  • Integrate evidence regarding advanced dosing strategies into individualized management plans for patients with DME

Benefits of Attending

  • Insights into patient beliefs about nAMD, DME, and their treatment
  • Opportunities for patient education
  • Big picture on how new anti-VEGFs can fit into patient management

Here is the full list of Virtual CE Credits available from EnVision:

Click here for details!

Friday February 16

  • Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention
    • 12:00pm–1:00pm Atlantic Standard Time

 Saturday February 17

  • Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
    • 7:00am–8:00am Atlantic Standard Time
  •  Surv.AI Says: Real World Insights and Answers into nAMD & DME Patient Burden and Evolving Management Strategies
    • 12:45pm–1:45pm Atlantic Standard Time 

Sunday February 18

  • Assessing the Evidence for Extending Treatment Intervals in nAMD & DME Management – Expert Insights into Innovative Approaches
    • 6:45am–7:45am Atlantic Standard Time
  • Cases & Conversations ™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
    • 5:30pm–6:30pm Atlantic Standard Time
  • Optimizing Outcomes in Glaucoma Management – Applying Evidence to Practice With a Multitude of Treatment Options
    • 6:30pm–7:30pm Atlantic Standard Time